MG 4101
Alternative Names: Allogeneic natural killer cells – GC Biopharma; Allogeneic NK cells; MG-4101Latest Information Update: 01 Apr 2022
At a glance
- Originator Green Cross
- Developer GC Biopharma; Samsung Medical Center; Seoul National University Hospital
- Class Immunotherapies; Natural killer cell therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Liver cancer; Solid tumours
- Phase I/II Non-Hodgkin's lymphoma
- No development reported Lymphoma
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 11 Dec 2021 Safety and efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
- 05 Dec 2020 Efficacy and adverse events data from a phase I/II trial in Non-Hodgkin's lymphoma presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2020)